For too long, psychiatry has relied solely on clinical observation to prescribe treatments, overlooking the biological differences that impact how patients respond to medication. This trial-and-error approach leads to inconsistent outcomes, with many patients cycling through multiple treatments - often without success. As a result, while there are approximately 21 million patients in the US with major depressive disorder (MDD), approximately 50% are not on therapy. Drawing inspiration from advances in oncology and genetic medicine, precision medicine offers a groundbreaking opportunity to redefine psychiatry by providing targeted, personalized treatments for high-need populations that have seen little innovation. This panel will offer actionable insights and strategies to help navigate this exciting new era of precision neuropsychiatry, ensuring a future where targeted treatments are determined through deep neurobiological insights, enabling both clinicians and patients to have greater confidence in the decision-making process and personalized treatment plan.